Activation of the c-myc proto-oncogene by one of the immunoglobulin (Ig) loci after chromosomal translocation is a consistent feature of Burkitt's lymphoma. Dierent subtypes of this tumor vary in the molecular architecture of the translocation region. In most cases there are no known regulatory elements of the Ig locus neighboring the oncogene and this considerably obscures the mechanism of its deregulation. In order to assess possible oncogene activation signals, we produced an experimental translocation region by insertion of a c-myc gene about 50 kb from the IgH intron enhancer in a yeast arti®cial chromosome (YAC) containing a 220 kb region of the human Ig heavy chain (IgH) locus. Single copy integration of this YAC into the genome of mouse embryonic stem (ES) cells was achieved by spheroplast fusion. Chimeric mice derived from these ES cells developed monoclonal B-cell lymphomas expressing surface IgM by 8 ± 16 weeks of age. The IgH/c-myc translocus showed dierent V H DJ H rearrangement in almost all tumors without any alterations of the distance between c-myc and the IgH intron enhancer. This mouse model can be used for the in vivo analysis of c-myc deregulation and the tumor formation capacity of the IgH locus in aberrant rearrangements.
Keywords: c-myc deregulation; chromosomal translocation; Burkitt's lymphoma; translocus control; immunoglobulin intron enhancer Chromosomal translocation by which the c-myc protooncogene on region 8q24 is juxtaposed to one of the immunoglobulin (Ig) gene loci on chromosomes 14q32 (IgH), 2p11 (Igk), or 22q11 (Igl) are consistently found in Burkitt's lymphomas. The translocated and often mutated c-myc gene is expressed and deregulated at various levels ± these include alternative promoters, transcription elongation and mRNA stability ± whereas the non-translocated allele is usually transcriptionally silent (Spencer and Groudine, 1991) . Exogenous expression of c-myc in transgenic mice can induce dierent types of neoplastic proliferation depending on promoter/enhancer combinations which drive transgene expression (Stewart et al., 1984; Spanopoulou et al., 1989; Sandgren et al., 1991) . Lymphoid tumors have been found in mice carrying various minigene constructs with c-myc under the control of a murine or human IgH intron enhancer (Adams et al., 1985; Suda et al., 1987; Schmidt et al., 1988; Yukawa et al., 1989) . These results supported the notion that deregulation of c-myc in Burkitt's lymphoma is achieved by Ig gene sequences which subsequently control a critical step in tumorigenesis.
In Burkitt's lymphoma cells, however, translocation of c-myc into the vicinity of a known Ig enhancer have rarely been documented (Hayday et al., 1984) and in the predominant t(8;14) translocations the breakpoints on both chromosomes involved can vary considerably (Croce, 1993) . As a result the IgH intron enhancer is either located a long distance upstream of the c-myc gene (usually more than 100 kb) or missing altogether from the translocation product carrying the oncogene (Rabbitts and Boehm, 1991) . In mice various enhancer elements have been discovered at the 3' end of the IgH locus which in combination can eectively deregulate an adjacent c-myc promoter after transfection into Burkitt's lymphoma cell lines (Madisen and Groudine, 1994) . Nevertheless, the possible involvement of such crucial regulatory sequences in tumor formation has not been analysed in animals, nor indeed have equivalent control elements been identi®ed in the human IgH locus.
Expression studies of large gene loci in vivo have been facilitated by techniques to transfer yeast arti®cial chromosomes (YACs) into mouse embryonic stem (ES) cells or oocytes Schedl et al., 1996) . Appropriate developmental control of the human b-globin locus present on a YAC transgene has been reported (Peterson et al., 1993) and sitespeci®c modi®cations of the locus identi®ed the function of speci®c regulatory sequences (Bungert et al., 1995) . In an attempt to study the impact of a large part of the IgH locus on a translocated protooncogene we have inserted a c-myc gene into a YAC containing 220 kb of the human IgH locus in germline con®guration. This YAC was transferred into ES cells by protoplast fusion and the resulting chimeric mice were monitored for tumor formation. We show that a single copy of this YAC with the human c-myc gene about 50 kb away from the IgH intron enhancer resulted in the rapid induction of B-cell lymphomas in chimeric mice.
Results

Construction of the human IgH/c-myc YAC and transfer into ES cells
The HuIgH YAC contains an authentic 220 kb region of the human heavy chain locus in germline configuration, including ®ve variable (V) region gene segments, the diversity (D) segment cluster, the joining (J) segments and the m and d constant (C) region genes (BruÈ ggemann and Neuberger, 1996) . The c-myc gene on a 8.6 kb EcoRI ± HindIII fragment including all three exons with adjacent lg switch region sequence was derived from the Burkitt's lymphoma cell line Raji . In order to create a translocation region (Figure 1 ) the c-myc gene and a selectable marker gene for ES cells (neo r ) were introduced site-speci®cally into the acentric arm of the HuIgH YAC. This was performed by cotransformation of YAC containing yeast with plasmids pRBura3 (Figure 1 ) and pLNA (Davies et al., 1992) . Yeast clones showing homologous integration of a single copy of pRBura3 and tandem copies of pLNA, needed for ecient selection of ES cells were identi®ed by a 10.9 kb EcoRI fragment hybridizing to the c-myc probe, two SalI fragments of 11.4 kb and 8.9 kb hybridizing to the neo probe and the expected increase in size of the undigested YAC by 30 kb (data not shown).
The translocation locus termed IgH/c-myc YAC (yeast clone N1) was transferred into HM-1 ES cells (Selfridge et al., 1992) by fusion with yeast spheroplasts followed by G418 selection . Several G418 resistant ES cell clones were obtained and Southern hybridization with probes speci®c for dierent regions of the YAC indicated that in clones N1-21 and N1-22 a single and complete copy was integrated at dierent sites in the ES cell genome (Figure 2 , left panels). Single copy integration was evident from hybridization with the amp probe which detected a 7.6 kb internal EcoRI fragment of the modi®ed right YAC arm and two additional fragments of variable size. These derive from the distal EcoRI fragments of the left (5.5 kb) and modi®ed right (5.1 kb) YAC arm and their increase in size is therefore dependent on the integration site of the YAC which in the case of N1-22 resulted in comigrating fragments. The presence of both YAC arms was further con®rmed by additional digests (data not shown) whilst hybridization with total yeast DNA showed that clones N1-21 and N1-22 in contrast to others (e.g. N1-25) had not taken up any signi®cant amounts of yeast DNA in addition to the YAC ( Figure  2 , right panel).
Tumor formation in chimeric mice derived from transgenic ES cells
The ES cell clones N1-21 and N1-22 containing the IgH/c-myc YAC were used for injection into BALB/c blastocysts . A total of nine chimeric mice were born with a coat color contribution obtained from the ES cells of 25 ± 70%. By the age of 8 ± 16 weeks six of these chimeras, four derived from N1-21 (21-2, 21-3, 21-4 and 21-5) and two from N1-22 (22-1 and 22-2), had developed tumors. Their illness became uniformly manifested by a hunched posture, rued fur and the formation of a prominent lump on the head. The latter turned out to be caused by soft, diuse tumor tissue located intracranially adherent to the bones and clearly separate from the brain. An autopsy showed that almost all chimeras suered from additional and larger tumor tissues, located in the abdomen and/or chest, presented as soft tumor masses with non-diuse borders which could contribute to about 10% of their body weight. Other abnormalities observed were a frequent enlargement of the spleen and/or the thymus while none of the six non-chimeric littermates (i.e. chimerism undetectable by the coat color) showed any signs of illness. . A detailed map of the modi®ed right YAC arm is given below. The switch region sequence (Sg/Sm) the c-myc exons (1 ± 3), and one copy of the yeast URA3 gene originated from integration of pRBura3 whereas the yeast LYS2 marker and the neo r genes are derived from pLNA (R, EcoRI). Methods: The yeast URA3 gene on a 1.1 kb HindIII fragment (Rose et al., 1984) was cloned into the HindIII site of pUCRB19RH7 Hamlyn and Rabbitts, 1983 ) to obtain the 12.4 kb plasmid pRBura3 with URA3, c-myc and the ampicillin resistance gene in the same transcriptional orientation. Co-transformation of spheroplasted yeast cells AB1380 containing the HuIgH YAC with pRBura3, linearised with Ncol, and pLNA (Davies et al., 1992) , linearised with Scal, was performed as described and yeast clones growing in lysine de®cient medium were screened for homologous integration events by Southern analysis
Lymphoid origin of the tumors and integrity of the translocus
The tumors were of lymphoid origin and tumor tissues dissected from dierent sites of the same mouse were monoclonal. This was revealed by Southern analysis of the endogenous mouse IgH locus where one or two rearranged fragments of dierent sizes, but speci®c for the individual mouse, were found in all tumors (data not shown). In addition¯ow cytometry analyses of primary tumor tissues from ®ve dierent chimeras were performed using antibodies against the B-cell surface marker B220(CD45R) and mouse IgM. In all cases well over 80% of the cells stained brightly for both markers (data not shown).
In view of the chimeric character of the tumorbearing mice, tumor cells were analysed for the presence of the oncogene. Southern blot analysis of EcoRI digests, as presented in Figure 3A , showed the endogenous mouse c-myc gene on a 21 kb fragment and human c-myc on a 10.9 kb fragment in DNA of all tumor tissues, with the signal intensity indicating that all tumor cells were derived from the manipulated ES cells. The integrity of the IgH/c-myc translocus was assessed by analysing V H DJ H rearrangments of the human IgH region. Hybridization of BamHI ± HindIII digests with the human Em probe showed a germlinesize fragment of 5.8 kb in tumor DNA from chimera 21-5 whilst in tumor samples from all other chimeras (e.g. 21-3 and 22-1, Figure 3B ) dierent rearrangements were detected. However, as rearrangements could also potentially indicate gross alterations of the transgene locus we established the presence of the neighboring BamHI ± HindIII fragment by hybridization with the Cm probe. In tumor samples of all chimeras a germlinesize fragment (10.5 kb) was detected ( Figure 3C and data not shown). In the human IgH locus a Spel fragment of about 100 kb accommodating V H 6-1, the D region, Cm and part of Cd (see Figure 1 ) would also be altered by V H DJ H recombination. In Figure 3D hybridization with the V H 6-1 probe highlights this Spel fragment in germline con®guration in N1-21 ES cells and in tumor DNA from chimera 21-5, where no rearrangement could be detected with the Em probe. No alteration of the Spel brand was found in the tumor cells of chimera 22-1. The shortened BamHI ± HindIII fragment hybridizing to Em is therefore most likely due to a DJ H rearrangement involving D H Q52 and resulting in a deletion of just 1.4 kb from the 100 kb Spel fragment. In the tumor DNA from chimera 21-3, however, the Spel fragment was shortened to about 30 kb ( Figure 3D ) as would be expected for a V H DJ H rearrangement involving V H 6-1. In agreement with these interpretations, the V H 6-1 probe hybridized to germlinesize EcoRI fragments in chimeras 21-5 and 22-1 and to a rearranged fragment of 9.4 kb in chimera 21-3 (data not shown). To verify the integrity of the region between the intron enhancer and c-myc in the tumor cells, Spel fragments at the 3' end of the IgH/c-myc translocus were analysed in tumor DNA from three dierent chimeras. As shown in Figures 3E and 3F , germline fragments of 9.0 and 18 kb were detected by the dM2 probe or the 3'IgH probe, respectively, in all samples. Thus hybridization results show that despite frequent (V H )DJ H recombination the 50 kb region from Em to c-myc is unaltered in all tumors analysed.
Discussion
In spite of the molecular characterization of many dierent chromosomal breakpoints found in Burkitt's lymphomas, it is still unclear which element(s) of an Ig locus is (are) responsible for the deregulation of the translocated c-myc gene. In particular, the large distance between the oncogene and putative regulatory sequences hampers the in vivo analysis. We have used the YAC technology to modify and introduce a 260 kb human IgH/c-myc translocus into the mouse genome. The experiments showed that c-myc activation and induction of B-cell lymphomas in mice is achieved despite separating the oncogene about 50 kb from a known enhancer. This strategy of introducing a modi®ed YAC into mice proved useful as a model for the in vivo study of oncogene activation after chromosomal translocation. Activation of a c-myc gene linked to an Ig enhancer on a minigene construct has been extensively studies in transgenic mice produced by injection of DNA into oocytes (Adams et al., 1985; Suda et al., 1987; Schmidt et al., 1988; Yukawa et al., 1989) . This technique usually results in tandem integration of multiple copies of the transgene into 6 cells (digested in agarose blocks) or 6 mg ES cell DNA (this equals 10 6 diploid genomes) was applied per lane. Hybridization to speci®c probes, c-myc, a 1.2 kb SmaI fragment from pUCRB19RH7 , Em, a 0.8 kb BglII ± HindIII fragment from the human J H -Cm intron (Hayday et al., 1984) , and amp, a 1.5 kb Pvull ± Scal fragment from pBluescript (Stratagene), or total yeast DNA, isolated from S. cerevisiae strain AB1380 and digested with Sau3A, is indicated in bold and sizes are in kb. Note that hybridization with total yeast DNA also detects cross-hybridizing fragments (Davies et al., 1993) highlighted in all ES cell clones including unmanipulated HM-1 cells the genome (e.g. up to 40 copies are reported by Suda et al., 1987) . A high copy number of a c-myc transgene might have a stimulating eect on tumor induction since c-myc ampli®cation has been associated with a variety of human tumors (Brison, 1993) . However, in our transgenic mouse model single copy integration of the IgH/c-myc YAC into the ES cell genome was achieved and proofed to be sucient for early tumor formation in chimeric mice. The experiments were successful with two independently derived ES cell clones which indicated that the integration site of the transgene did not play a critical role in tumor formation.
The human c-myc gene in the experiments was derived from the translocated allele of the Burkitt's lymphoma cell line Raji, where no Ig enhancer element is located adjacent to the oncogene . This means that the IgH/c-myc translocus contains only one known Ig enhancer located about 50 kb upstream of the introduced c-myc gene. This distance is not altered in the lymphoid tumors although the translocus showed V H DJ H rearrangement in most cases. The view that large linear distances do not prevent enhancer function was recently analysed in transfection experiments where Igk enhancer elements located about 30 kb distal to c-myc in¯uenced c-myc expression in lymphoid cells (Mautner et al., 1996) . However, it still needs to be shown whether this holds true in transgenic animals, as con¯icting results between c-myc gene expression in vitro and in vivo have been reported (Morello et al., 1993; Lavenu et al., 1994) .
Tumor formation provoked by Em/c-myc minigene constructs typically involved the lymphatic system with swelling of the lymph nodes as the ®rst sign of the illness. The tumors represented dierent stages of B-cell development with pre-B cell stages being predominant (Adams et al., 1985; Harris et al., 1988a, b; Schmidt et al., 1988; Suda et al., 1987) . In contrast, the tumors of all six chimeras in our study developed as soft tumor masses inside the skull, in the abdomen and/or the chest without an involvement of any lymph nodes. Buluwela and Rabbitts, 1988) ; Cm, a 1.2 kb EcoRl fragment from lC75 (Milstein et al., 1984) ; dM2, a 0.35 kb PCR fragment from the human Cdgene (Wagner et al., 1996) ; 3'IgH, a 0.4 kb EcoRI fragment from plasmid pM5-1-23, which contains 3.4 kb of DNA adjacent to the acentric arm of the HuIgH YAC and was obtained by plasmid rescue (C Mundt, unpublished) , and c-myc and Em described in Figure 2 ). Separation was on conventional TAE gels except for D where pulsed-®eld gel electrophoresis (1% agarose gel in 0.56TBE using a LKB Pulsaphor 2015 equipment with 5 s switch time for 27 h followed by 10 s switch time for 6 h at 140 V and 128C) was performed. Germline or unaltered transgene con®gurations are indicated by arrowheads usually also slg + (typically IgM, GunveÂ n et al., 1980) and the tumors are formed primarily at extranodal sites (Magrath, 1990 ); e.g. in the jaws (Burkitt, 1958) . the abdomen or the central nervous system (GutieÂ rrez et al., 1992) . Phenotypic variations may be dependent on the dierent mouse strains used (Yukawa et al., 1989) , however, it is likely that the somewhat dierent tumor phenotype identi®ed in our experiment is due to the large Ig gene region linked to c-myc. Thus, the predominance of pre-B cell tumors in Em-myc minigene mice may depend on the activity of Em early in B-cell development (Gerster et al., 1986) . In our mouse model, the distance of Em and c-myc and/or not yet identi®ed control sequences in the Ig gene region might modulate Em enhancer activity and, thus restrict the activation of c-myc in a dierent subset of B lymphocytes. Alternatively a regulatory element dierent from Em but located in cis on the transgenic Ig gene locus might be responsible for c-myc activation.
A dierent approach to model chromosomal translocations in transgenic mice by use of the cre/ loxP system has been reported recently (Smith et al., 1995) . A t(12;15) translocation was achieved in ES cells although no tumor induction in mice was obtained. Compared to this strategy, the introduction of translocation YACs into mice has the advantage that the methodology to modify YACs is now well established (Markie, 1996) and this allows functional identi®cation of control sequences on large gene loci. For this, our emphasis is on deletion strategies to identify the relevance of the Em enhancer in oncogene activation. By transferring modi®ed translocation YACS into the mouse genome and monitoring tumor formation we will be able not only to clarify the role of distantly located control elements, but also to use this mouse model for identifying ecient strategies to suppresss tumor formation.
